Single-Use unit and Process Analytical Infrared Spectroscopy

Informazioni relative al progetto

SUPAIR Spectroscopy

ID dell’accordo di sovvenzione: 954732

DOI

10.3030/954732

Progetto chiuso

Data della firma CE 30 Aprile 2020

Data di avvio 1 Maggio 2020

Data di completamento 30 Aprile 2022

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 1 880 327,50

Contributo UE

€ 1 316 229,25

Coordinato da

IRUBIS GMBH
Germany

Periodic Reporting for period 2 - SUPAIR Spectroscopy (Single-Use unit and Process Analytical Infrared Spectroscopy)

Periodo di rendicontazione: 2021-02-01 al 2022-04-30

Sintesi del contesto e degli obiettivi generali del progetto

IRUBIS GmbH developed within the project a novel analytical device that enables continuous real-time monitoring of bioprocesses using mid-infrared spectroscopy with a single use flow cell. Its market is in process development and manufacturing of biological drugs, such as vaccines. The objective of ‘SUPAIR Spectroscopy’ project was to develop the mid-infrared spectroscopy system in line with the biopharma user requirements and to lay the groundwork for successful market commercialization. The validation and feedback by biopharma companies was essential for the project. Additionally, their feedback as well as the promotion of the results laid the foundation for the commercialization strategy.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the first 9 month of the action the hardware and software were developed: a monitoring and control solution, including an algorithm that can monitor glucose and lactate, without extensive calibration model building and a control feature to keep the glucose concentration at a constant level. During the second period ‘Monipa’ was validated, and the manufacturing of the analytical device was adapted based on the feedback from biopharma users to achieve a suitable process analytical technology for the biopharma industry. In parallel a business innovation plan and commercialization plan has been developed and dissemination as well as exploitation activities conducted.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We see the future impact of ‘Monipa’ on the one hand by enabling an increase of the product gain and to achieve higher quality of biopharmaceutical drugs by a continuous control of the nutrient parameter in the bioprocess. On the other hand, a continuous control and real-time monitoring of nutrients and metabolites in the bioprocess leads to a higher process know-how and decrease the time for process development. In a consequence the new technology brings biopharmaceuticals faster to the patient.

Monipa, real-time monitoring of bioprocesses